Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial

Loi, S; Giobbie-Hurder, A; Gombos, A; Bachelot, T; Hui, R; Curigliano, G; Campone, M; Biganzoli, L; Bonnefoi, H; Jerusalem, G; Bartsch, R; Rabaglio-Poretti, M; Kammler, R; Maibach, R; Smyth, MJ; Di Leo, A; Colleoni, M; Viale, G; Regan, MM; Andre, F;

Loi, S (reprint author), Univ Melbourne, Div Res & Clin Med, Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia.

LANCET ONCOLOGY, 2019; 20 (3): 371

Abstract

Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索